Advertisement

Topics

Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole

07:25 EDT 12 Jul 2018 | SCRIP

Positive top-line results from the Phase IIb DOVE study of Scynexis's SCY-078, and progress with a new intravenous formulation, suggest...

      

Related Stories

 

Original Article: Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole

NEXT ARTICLE

More From BioPortfolio on "Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole"

Advertisement
Quick Search
Advertisement
Advertisement